Skip to main content

Table 1 Clinical information of LUAD and LUSC in TCGA datasets

From: Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy

Variables

LUAD (522)

LUSC (504)

Number

Percentage (%)

Number

Percentage (%)

Age

    

 < 65

223

42.72

170

33.73

 ≥ 65

280

53.64

325

64.48

 Unknow

19

3.64

9

1.79

Gender

    

 Male

242

46.36

373

74.01

 Female

280

53.64

131

25.99

Survival status

242

46.36

  

 Alive

334

63.98

286

56.75

 Dead

188

36.02

218

43.25

Survival time/days

902.51 ± 891.28

 

968.42 ± 957.61

 

Clinical stage

    

 Stage I–II

403

77.20

408

80.95

 Stage III–IV

111

21.26

92

18.25

 Unknow

8

1.53

4

0.79

T stage

    

 I–II

453

86.78

409

81.15

 III–IV

66

12.64

95

18.85

 TX

3

0.57

  

N stage

    

 N0

335

64.18

320

63.49

 NX

11

2.11

6

1.19

 N1–3

175

33.52

178

35.32

 Unknow

1

0.19

  

M stage

    

 M0

353

67.62

414

82.14

 M1

25

4.79

7

1.39

 MX

140

26.82

79

15.67

 Unknow

4

0.77

4

0.79